K-115 clinical pharmacology study

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222406

Enrollment

Registered

2014-02-27

Start date

2014-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy , diabetic macular edema

Interventions

investigational material(s) Generic name etc : K-115 INN of investigational material : Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with type 2 diabetes mellitus 2.Patients with nonproliferative diabetic retinopathy 3.Patients with diabetic macular edema

Exclusion criteria

Exclusion criteria: 1.Patients whose best corrected visual acuity is less than 0.1 2.Patients who are not able to abstain medications that have the potential to affect on the evaluation of K-115 3.Patients with any trouble to measure ocular blood flow and retinal thickness etc.

Design outcomes

Primary

Measure	Time frame
Efficacy:Ocular blood flow,macular edema Safety:Adverse event (AE) and adverse drug reaction (ADR) Efficacy:Change in the volume and the percentage of ocular blood flow and retinal thickness Safety:AE and ADR	—

Secondary

Measure	Time frame
N/A N/A	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026